Covalent heterobivalent inhibitor design for inhibition of IgE-dependent penicillin allergy in a murine model

Peter E. Deak, Baksun Kim, Byunghee Koh, Amina Abdul Qayum, Tanyel Kiziltepe, Mark Kaplan, Basar Bilgicer

Research output: Contribution to journalArticle

Abstract

Drug allergies occur when hapten-like drug metabolites conjugated to serum proteins, through their interactions with specific IgE, trigger allergic reactions that can be life threatening. A molecule termed covalent heterobivalent inhibitor (cHBI) was designed to specifically target drug hapten-specific IgE to prevent it from binding drug-haptenated serum proteins. cHBI binds the two independent sites on a drug hapten-specific Ab and covalently conjugates only to the specific IgE, permanently inhibiting it. The cHBI design was evaluated via ELISA to measure cHBI-IgE binding, degranulation assays of rat basophil leukemia cells for in vitro efficacy, and mouse models of ear swelling and systemic anaphylaxis responses for in vivo efficacy. The cHBI design was evaluated using two separate models: one specific to inhibit penicillin G-reactive IgE and another to inhibit IgE specific to a model compound, dansyl. We show that cHBI conjugated specifically to its target Ab and inhibited degranulation in cellular degranulation assays using rat basophil leukemia cells. Furthermore, cHBIs demonstrated in vivo inhibition of allergic responses in both murine models. We establish the cHBI design to be a versatile platform for inhibiting hapten/IgE interactions, which can potentially be applied to inhibit IgE-mediated allergic reactions to any drug/small-molecule allergy.

Original languageEnglish (US)
Pages (from-to)21-30
Number of pages10
JournalJournal of Immunology
Volume203
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Penicillins
Immunoglobulin E
Hypersensitivity
Haptens
Pharmaceutical Preparations
Basophils
Dansyl Compounds
Blood Proteins
Leukemia
Drug Hypersensitivity
Penicillin G
Anaphylaxis
Ear
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Covalent heterobivalent inhibitor design for inhibition of IgE-dependent penicillin allergy in a murine model. / Deak, Peter E.; Kim, Baksun; Koh, Byunghee; Qayum, Amina Abdul; Kiziltepe, Tanyel; Kaplan, Mark; Bilgicer, Basar.

In: Journal of Immunology, Vol. 203, No. 1, 01.01.2019, p. 21-30.

Research output: Contribution to journalArticle

Deak, Peter E. ; Kim, Baksun ; Koh, Byunghee ; Qayum, Amina Abdul ; Kiziltepe, Tanyel ; Kaplan, Mark ; Bilgicer, Basar. / Covalent heterobivalent inhibitor design for inhibition of IgE-dependent penicillin allergy in a murine model. In: Journal of Immunology. 2019 ; Vol. 203, No. 1. pp. 21-30.
@article{fa47ae3355ba43aea9873f98eadde880,
title = "Covalent heterobivalent inhibitor design for inhibition of IgE-dependent penicillin allergy in a murine model",
abstract = "Drug allergies occur when hapten-like drug metabolites conjugated to serum proteins, through their interactions with specific IgE, trigger allergic reactions that can be life threatening. A molecule termed covalent heterobivalent inhibitor (cHBI) was designed to specifically target drug hapten-specific IgE to prevent it from binding drug-haptenated serum proteins. cHBI binds the two independent sites on a drug hapten-specific Ab and covalently conjugates only to the specific IgE, permanently inhibiting it. The cHBI design was evaluated via ELISA to measure cHBI-IgE binding, degranulation assays of rat basophil leukemia cells for in vitro efficacy, and mouse models of ear swelling and systemic anaphylaxis responses for in vivo efficacy. The cHBI design was evaluated using two separate models: one specific to inhibit penicillin G-reactive IgE and another to inhibit IgE specific to a model compound, dansyl. We show that cHBI conjugated specifically to its target Ab and inhibited degranulation in cellular degranulation assays using rat basophil leukemia cells. Furthermore, cHBIs demonstrated in vivo inhibition of allergic responses in both murine models. We establish the cHBI design to be a versatile platform for inhibiting hapten/IgE interactions, which can potentially be applied to inhibit IgE-mediated allergic reactions to any drug/small-molecule allergy.",
author = "Deak, {Peter E.} and Baksun Kim and Byunghee Koh and Qayum, {Amina Abdul} and Tanyel Kiziltepe and Mark Kaplan and Basar Bilgicer",
year = "2019",
month = "1",
day = "1",
doi = "10.4049/jimmunol.1900225",
language = "English (US)",
volume = "203",
pages = "21--30",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Covalent heterobivalent inhibitor design for inhibition of IgE-dependent penicillin allergy in a murine model

AU - Deak, Peter E.

AU - Kim, Baksun

AU - Koh, Byunghee

AU - Qayum, Amina Abdul

AU - Kiziltepe, Tanyel

AU - Kaplan, Mark

AU - Bilgicer, Basar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Drug allergies occur when hapten-like drug metabolites conjugated to serum proteins, through their interactions with specific IgE, trigger allergic reactions that can be life threatening. A molecule termed covalent heterobivalent inhibitor (cHBI) was designed to specifically target drug hapten-specific IgE to prevent it from binding drug-haptenated serum proteins. cHBI binds the two independent sites on a drug hapten-specific Ab and covalently conjugates only to the specific IgE, permanently inhibiting it. The cHBI design was evaluated via ELISA to measure cHBI-IgE binding, degranulation assays of rat basophil leukemia cells for in vitro efficacy, and mouse models of ear swelling and systemic anaphylaxis responses for in vivo efficacy. The cHBI design was evaluated using two separate models: one specific to inhibit penicillin G-reactive IgE and another to inhibit IgE specific to a model compound, dansyl. We show that cHBI conjugated specifically to its target Ab and inhibited degranulation in cellular degranulation assays using rat basophil leukemia cells. Furthermore, cHBIs demonstrated in vivo inhibition of allergic responses in both murine models. We establish the cHBI design to be a versatile platform for inhibiting hapten/IgE interactions, which can potentially be applied to inhibit IgE-mediated allergic reactions to any drug/small-molecule allergy.

AB - Drug allergies occur when hapten-like drug metabolites conjugated to serum proteins, through their interactions with specific IgE, trigger allergic reactions that can be life threatening. A molecule termed covalent heterobivalent inhibitor (cHBI) was designed to specifically target drug hapten-specific IgE to prevent it from binding drug-haptenated serum proteins. cHBI binds the two independent sites on a drug hapten-specific Ab and covalently conjugates only to the specific IgE, permanently inhibiting it. The cHBI design was evaluated via ELISA to measure cHBI-IgE binding, degranulation assays of rat basophil leukemia cells for in vitro efficacy, and mouse models of ear swelling and systemic anaphylaxis responses for in vivo efficacy. The cHBI design was evaluated using two separate models: one specific to inhibit penicillin G-reactive IgE and another to inhibit IgE specific to a model compound, dansyl. We show that cHBI conjugated specifically to its target Ab and inhibited degranulation in cellular degranulation assays using rat basophil leukemia cells. Furthermore, cHBIs demonstrated in vivo inhibition of allergic responses in both murine models. We establish the cHBI design to be a versatile platform for inhibiting hapten/IgE interactions, which can potentially be applied to inhibit IgE-mediated allergic reactions to any drug/small-molecule allergy.

UR - http://www.scopus.com/inward/record.url?scp=85068428802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068428802&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1900225

DO - 10.4049/jimmunol.1900225

M3 - Article

C2 - 31101666

AN - SCOPUS:85068428802

VL - 203

SP - 21

EP - 30

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -